Top

Published in:

01-09-2018 | Maternal-Fetal Medicine

Tocolysis with the β₂-sympathomimetic fenoterol does not increase the occurrence of infantile hemangioma in preterm and term infants

Authors: Hannes Hudalla, Christian Karmen, Thomas Bruckner, Stephanie Wallwiener, Herbert Fluhr, Zoe Michael, Alexander Freis, Holger Maul, Thomas Strowitzki, Johannes Pöschl, Ruben-J. Kuon

Published in: Archives of Gynecology and Obstetrics | Issue 3/2018

Abstract

Purpose

β₂-sympathomimetics are used in obstetrics as tocolytic agents, despite a remarkable profile of side effects. Recently, the β₂-sympathomimetic tocolytic drug hexoprenaline was identified as an independent risk factor for the development of infantile hemangioma (IH) in preterm infants. The aim of this study was to evaluate whether this observed effect was applicable to other β₂-mimetic tocolytic agents like fenoterol.

Methods

Clinical prospectively collected data of all infants born between 2001 and 2012 and admitted to the neonatal intensive care unit (NICU) at Heidelberg University Hospital and respective maternal data were merged. For the current retrospective cohort study, cases (IH) were matched to controls (no IH) at a ratio of 1:4, adjusting for birth weight, gestational age, gender and multiple gestations. Prenatal exposure to fenoterol and perinatal outcome were analyzed in the total cohort and in subgroups.

Results

N = 5070 infants were admitted to our neonatal department, out of which n = 172 infants with IH were identified and compared to n = 596 matched controls. Exposure to fenoterol was not associated with a higher rate of IH in the total matched population (OR 0.926, 95% CI 0.619–1.384) or in a subgroup of neonates < 32 weeks of gestation or with a birth weight < 1500 g (OR 1.127, 95% CI 0.709–1.791). In the total matched population, prenatal exposure to glucocorticoids was associated with a reduced occurrence of IH (OR 0.566, 95% CI 0.332–0.964) and neonates with IH showed a prolonged total hospital stay compared to controls (69 vs. 57 days, p = 0.0033). Known risk factors for IH were confirmed by our large study cohort and included female gender, low birth weight, preterm birth and multiple gestations (all p < 0.005).

Conclusions

Exposure to fenoterol during pregnancy does not increase the occurrence of IH. Further studies are needed to explore differences in the risk profiles of different β₂-sympathomimetic tocolytic drugs.

Blencowe H, Cousens S, Chou D et al (2013) Born too soon: the global epidemiology of 15 million preterm births. Reprod Health 10(Suppl 1):S2CrossRefPubMedPubMedCentral

Martin JA, Hamilton BE, Ventura SJ et al (2013) Births: final data for 2011. Natl Vital Stat Rep 62(1):1–69–1–72

Beck S, Wojdyla D, Say L et al (2010) The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bull World Health Organ 88:31–38. https://doi.org/10.2471/BLT.08.062554 CrossRefPubMed

Haas DM, Caldwell DM, Kirkpatrick P et al (2012) Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. BMJ 345:e6226CrossRefPubMedPubMedCentral

Haas DM, Imperiale TF, Kirkpatrick PR et al (2009) Tocolytic therapy: a meta-analysis and decision analysis. Obstet Gynecol 113:585–594. https://doi.org/10.1097/AOG.0b013e318199924a CrossRefPubMed

de Heus R, Mol BW, Erwich J-JHM et al (2009) Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study. BMJ 338:b744CrossRefPubMedPubMedCentral

Mayer M, Minichmayr A, Klement F et al (2013) Tocolysis with the β-2-sympathomimetic hexoprenaline increases occurrence of infantile haemangioma in preterm infants. Arch Dis Child Fetal Neonatal Ed 98:F108–F111. https://doi.org/10.1136/archdischild-2011-301030 CrossRefPubMed

Frieden IJ, Haggstrom AN, Drolet BA et al (2005) Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7–9, 2005, Bethesda, Maryland, USA. In: Pediatr Dermatol, pp 383–406

Léauté-Labrèze C, Harper JI, Hoeger PH (2017) Infantile haemangioma. Lancet 390:85–94. https://doi.org/10.1016/S0140-6736(16)00645-0 CrossRefPubMed

10.

Drolet BA, Esterly NB, Frieden IJ (1999) Hemangiomas in children. N Engl J Med 341:173–181. https://doi.org/10.1056/NEJM199907153410307 CrossRefPubMed

11.

Drolet BA, Swanson EA, Frieden IJ, Hemangioma Investigator Group (2008) Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J Pediatr 153:712–715e1. https://doi.org/10.1016/j.jpeds.2008.05.043 CrossRefPubMed

12.

Kilcline C, Frieden IJ (2008) Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol 25:168–173. https://doi.org/10.1111/j.1525-1470.2008.00626.x CrossRefPubMed

13.

Dclalz MD, Pjih MD, Pphh MD (2017) Infantile haemangioma. Lancet 390:85–94. https://doi.org/10.1016/S0140-6736(16)00645-0 CrossRef

14.

Smith CJF, Friedlander SF, Guma M et al (2017) Infantile hemangiomas: an updated review on risk factors, pathogenesis, and treatment. Birth Defects Res 109:809–815. https://doi.org/10.1002/bdr2.1023 CrossRefPubMed

15.

Hunjan MK, Schoch JJ, Anderson KR et al (2017) Prenatal risk factors for infantile hemangioma development. J Invest Dermatol 137:954–957. https://doi.org/10.1016/j.jid.2016.10.047 CrossRefPubMed

16.

Siegfried EC, Keenan WJ, Al-Jureidini S (2008) More on propranolol for hemangiomas of infancy. N Engl J Med 359:2846. https://doi.org/10.1056/nejmc086443 (author reply 2846–7) CrossRefPubMed

17.

Léauté-Labrèze C, la Roque de ED, Hubiche T et al (2009) Propranolol for severe hemangiomas of infancy. N Engl J Med 358:2649–2651. https://doi.org/10.1056/nejmc0708819 CrossRef

18.

Manunza F, Syed S, Laguda B et al (2010) Propranolol for complicated infantile haemangiomas: a case series of 30 infants. Br J Dermatol 162:466–468. https://doi.org/10.1111/j.1365-2133.2009.09597.x CrossRefPubMed

19.

Woody MM, Levy ML, Weinfeld AB (2016) Propranolol for preoperative management of a large infantile hemangioma. Pediatr Dermatol 33:e198–e200. https://doi.org/10.1111/pde.12850 CrossRefPubMed

20.

Ames JA, Sykes JM (2015) Current trends in medical management of infantile hemangioma. Curr Opin Otolaryngol Head Neck Surg 23:286–291. https://doi.org/10.1097/MOO.0000000000000170 CrossRefPubMed

21.

Murphy SN, Mendis M, Hackett K et al (2007) Architecture of the open-source clinical research chart from Informatics for Integrating Biology and the Bedside. AMIA Annu Symp Proc 2007:548–552PubMedCentral

22.

Karmen C, Ganzinger M, Kohl CD et al (2014) A framework for integrating heterogeneous clinical data for a disease area into a central data warehouse. Stud Health Technol Inform 205:1060–1064PubMed

23.

Kawabata H, Tran M, Hines P (2004) Using SAS^® to match cases for case control studies. SUGI 29. Princeton, New Jersey, 173–29

24.

Annabi B, Lachambre M-P, Plouffe K et al (2009) Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res 60:438–445. https://doi.org/10.1016/j.phrs.2009.05.005 CrossRefPubMed

25.

Storch CH, Hoeger PH (2010) Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 163:269–274. https://doi.org/10.1111/j.1365-2133.2010.09848.x CrossRefPubMed

26.

Murphy KE, Willan AR, Hannah ME et al (2012) Effect of antenatal corticosteroids on fetal growth and gestational age at birth. Obstet Gynecol 119:917–923. https://doi.org/10.1097/AOG.0b013e31825189dc CrossRefPubMed

27.

Haggstrom AN, Drolet BA, Baselga E et al (2006) Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics 118:882–887. https://doi.org/10.1542/peds.2006-0413 CrossRefPubMed

28.

Greco MF, Frieden IJ, Drolet BA et al (2016) Infantile hemangiomas in twins: a prospective cohort study. Pediatr Dermatol 33:178–183. https://doi.org/10.1111/pde.12781 CrossRefPubMed

29.

Munden A, Butschek R, Tom WL et al (2014) Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies. Br J Dermatol 170:907–913. https://doi.org/10.1111/bjd.12804 CrossRefPubMedPubMedCentral

30.

Dickison P, Christou E, Wargon O (2011) A prospective study of infantile hemangiomas with a focus on incidence and risk factors. Pediatr Dermatol 28:663–669. https://doi.org/10.1111/j.1525-1470.2011.01568.x CrossRefPubMed

Title: Tocolysis with the β2-sympathomimetic fenoterol does not increase the occurrence of infantile hemangioma in preterm and term infants
Authors: Hannes Hudalla
Christian Karmen
Thomas Bruckner
Stephanie Wallwiener
Herbert Fluhr
Zoe Michael
Alexander Freis
Holger Maul
Thomas Strowitzki
Johannes Pöschl
Ruben-J. Kuon
Publication date: 01-09-2018
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 3/2018
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-018-4830-5

At a glance: The STEP trials

Springer Medicine

Tocolysis with the β₂-sympathomimetic fenoterol does not increase the occurrence of infantile hemangioma in preterm and term infants

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Effect of iron supplementation during early pregnancy on the development of gestational hypertension and pre-eclampsia

Maternal, fetal and neonatal consequences associated with the use of crack cocaine during the gestational period: a systematic review and meta-analysis

The safety of fertility preservation for microinvasive cervical adenocarcinoma: a meta-analysis and trial sequential analysis

Functional outcomes of nerve-sparing laparoscopic eradication of deep infiltrating endometriosis: a prospective analysis using validated questionnaires

Early missed abortion is associated with villous angiogenesis via the HIF-1α/VEGF signaling pathway

The influence of seasonal variations on in vitro fertilization and fresh/frozen embryo transfer: a retrospective study